DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Dovonex (Calcipotriene Topical) - Summary



Dovonex® (calcipotriene cream) Cream, 0.005% contains calcipotriene monohydrate, a synthetic vitamin D3 derivative, for topical dermatological use.

Dovonex® (calcipotriene cream) Cream, 0.005%, is indicated for the treatment of plaque psoriasis. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established.

See all Dovonex indications & dosage >>


Media Articles Related to Dovonex (Calcipotriene Topical)

Psoriasis Patients Face Increased Risk of Heart Attacks and Death
Source: Medscape Medical News Headlines [2017.09.29]
People with psoriasis, a chronic inflammatory disease, may be more likely than others to experience heart attacks and strokes at least in part because inflammation damages their vascular system, a recent study suggests.
Reuters Health Information

How Safe Are Various Systemic Therapies for Pediatric Psoriasis?
Source: Medscape Dermatology Headlines [2017.09.26]
Both methotrexate and TNF inhibitors appear to be safe for the majority of children, though cost is a big consideration.
Reuters Health Information

Psoriasis Quiz: Test Your Medical IQ
Source: MedicineNet Psoriasis Specialty [2017.09.19]
Title: Psoriasis Quiz: Test Your Medical IQ
Category: MedicineNet Quiz
Created: 4/21/2011 3:23:00 PM
Last Editorial Review: 9/19/2017 6:17:30 PM

Severe Psoriasis Linked to Higher Risk of Earlier Death
Source: MedicineNet Psoriasis Specialty [2017.09.06]
Title: Severe Psoriasis Linked to Higher Risk of Earlier Death
Category: Health News
Created: 9/5/2017 12:00:00 AM
Last Editorial Review: 9/6/2017 12:00:00 AM

Is Psoriasis Contagious?
Source: MedicineNet Psoriasis Specialty [2017.09.05]
Title: Is Psoriasis Contagious?
Category: Diseases and Conditions
Created: 6/22/2015 12:00:00 AM
Last Editorial Review: 9/5/2017 12:00:00 AM

more news >>

Published Studies Related to Dovonex (Calcipotriene Topical)

Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. [2013]
and limbs... CONCLUSION: The topical suspension containing calcipotriene plus betamethasone

Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials. [2012]
plaque-type psoriasis... CONCLUSIONS: In two identically designed, phase III clinical trials,

A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial. [2010.11]
The calcipotriene/betamethasone dipropionate two-compound scalp formulation has been shown to be safe and effective in the treatment of scalp psoriasis over 8 weeks, but the patients studied were mainly White and non-Hispanic. The aim of this study was to evaluate the efficacy and safety of the two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients...

Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. [2010.11]
BACKGROUND: Calcipotriene has limited efficacy in treating psoriasis. By inhibiting proinflammatory cytokines such as interleukin-12, interleukin-23, and tumor necrosis factor-alfa, nicotinamide may enhance the efficacy of calcipotriene therapy when used in combination. OBJECTIVE: We sought to determine if the combination of nicotinamide with calcipotriene is more effective than either component alone... CONCLUSION: This study provides evidence that using the combination nicotinamide and calcipotriene may provide additional benefit in the topical treatment for patients with psoriasis and may be an adequate steroid-sparing substitute treatment. Copyright (c) 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris. [2010.08]
The two-compound ointment (Taclonex/Daivobet/Dovobet ointment) combining calcipotriene 50 microg/g and betamethasone 0.5 mg/g (as dipropionate) is very effective in the treatment of psoriasis vulgaris... No patients using the two-compound ointment for all 52 weeks or alternating four-weekly with calcipotriene had HPA axis suppression.

more studies >>

Clinical Trials Related to Dovonex (Calcipotriene Topical)

Molecular Effects of Topical Calcipotriene on Morphea [Recruiting]
This study will look into how topical treatment with synthetic Vitamin D3, calcipotriene ointment, used as standard of care, works in patients with morphea. Skin biopsies of morphea lesions before and after treatment with topical calcipotriene 0. 005% ointment will be analyzed for changes in RNA and protein. A skin biopsy of unaffected skin will also be obtained and used for a control. This is an initial study to look at the molecular effects of topical calcipotriene on human morphea-involved skin. This study will look at the differences between affected and unaffected skin. This study also will look at clinical outcomes in morphea patients and determine if there are any clinical predictors for improvement with the medication.

Actinic Keratosis Study [Recruiting]
The main purpose of this study is to determine the effectiveness of a new combination therapy for actinic keratosis. This study investigates a new indication for an FDA-approved topical medication, calcipotriol, for treatment of actinic keratosis, including how well it works and how safe it is when used in combination with the standard of care medication (5-fluorouracil) for the skin condition.

Efficacy and Safety Study of Calcipotriol Betamethasone Plus Calcipotriol in Sequential Therapy to Psoriasis [Completed]

LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis [Completed]
The purpose of this study is to compare the safety and effectiveness of a new topical LCD solution and a commercially available calcipotriol (Vitamin D) cream in reducing the symptoms of plaque psoriasis and improving the quality of life in adults.

Comparison of Indigo Naturalis Oil Extract and Calcipotriol Solution in Treating Psoriasis [Completed]
The purpose of this study is to compare the efficacy and safety of indigo naturalis oil extract and calcipotriol solution in the treatment of psoriatic nails, to show that indigo naturalis oil extract may be a good choice for treating nail psoriasis, and potentially an effective alternative for those who do not respond well to traditional therapy.

more trials >>


Based on a total of 1 ratings/reviews, Dovonex has an overall score of 6. The effectiveness score is 6 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.

Dovonex review by 29 year old female patient

Overall rating:  
Effectiveness:   Moderately Effective
Side effects:   No Side Effects
Treatment Info
Condition / reason:   Psoriasis
Dosage & duration:   .005% (dosage frequency: 1-2 times daily) for the period of 4 years
Other conditions:   None
Other drugs taken:   Clobetasol
Reported Results
Benefits:   Controlled the psoriasis, however did not reduce its presence.
Side effects:   a "halo" a few shades lighter than the natural skin tone was present around the site of application, which would last about 12-24 hours.
Comments:   I found this time-consuming to apply 1-2 times daily. Also, due to the "halo" effect, it was a little precarious to apply as well.

See all Dovonex reviews / ratings >>

Page last updated: 2017-09-29

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017